Diabetes News and Research

Latest Diabetes News and Research

Why addiction researchers are paying closer attention to GLP-1 drugs

A Journal of Clinical Investigation Viewpoint highlights growing evidence that GLP-1 receptor agonists, particularly semaglutide, may reduce alcohol consumption and some other substance-related outcomes by acting on brain systems involved in reward, motivation, stress, and emotion. However, the authors caution that efficacy for substance use disorders is not yet firmly established and call for further research into optimal dosing, treatment duration, patient selection, mechanisms, and effects across different addictions.

2 Sep 2026

Your weekend meal schedule may matter more than you think

In a prospective analysis of 104,806 adults from the NutriNet-Santé cohort, greater differences in meal timing between weekdays and weekends were associated with higher risks of cardiovascular disease and coronary heart disease in men over a median 8.1 years. The associations were strongest when weekend eating shifted earlier, while delayed weekend eating was linked specifically to coronary heart disease, with no association detected for cerebrovascular disease.

2 Sep 2026

Generative AI helps scientists design entirely new RNA transporters

Researchers at Helmholtz Munich and TUM have developed Synthetic Transfer Vehicles (STVs), an entirely new class of RNA transporters.

2 Sep 2026

Bridging science and family story to understand schizophrenia origins

Twin studies have placed the heritability of schizophrenia at roughly eighty percent for decades. Concordance between identical twins, who share the entire genome, does not reach fifty percent. Both figures are well established, and they do not fit together comfortably.

2 Sep 2026

Bacterial protein fragment corisin found to drive pulmonary fibrosis

A bacterial protein fragment called corisin drives the process of pulmonary fibrosis by infiltrating and disrupting the cell's quality-control system, researchers at the University of Illinois Urbana-Champaign and Mie University in Japan found in a new study.

2 Sep 2026

Digital health coaching moves into routine care for gestational diabetes

Researchers at University College Dublin (UCD) published the full study protocol for Bump2Baby & Me+ (B2B&Me+) today.

2 Sep 2026

ECG-CLIP improves heart disease detection using less labeled data

Clinicians often use a medical test called a 12-lead electrocardiogram (ECG) to diagnose heart problems, which uses electrodes placed on the chest and limbs to record the heart's electrical activity.

1 Sep 2026

Certain diabetes patients face higher ketoacidosis risk with SGLT2 drugs

Patients with type 2 diabetes who have high blood glucose levels, low body weight, or a history of ketoacidosis are at increased risk of developing this serious condition when treated with so-called SGLT2 inhibitors.

1 Sep 2026

Flavorings, colors and sweeteners emerge as UPF markers linked to depression risk

A prospective UK Biobank study of 171,818 adults found that greater estimated exposure to foods containing flavorings, coloring agents, and sweeteners was dose-dependently associated with a higher risk of incident depression over 10.7 years. The findings suggest that specific markers, rather than ultra-processed foods uniformly, may help explain associations between UPF consumption and depression risk.

1 Sep 2026

Researchers identify a previously unknown mechanism that can drive cancer cachexia

Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich (TUM), have identified a previously unknown mechanism that can drive cancer cachexia – a wasting process in the body that primarily affects muscle and fat tissue.

1 Sep 2026

Blocking a key protein protects against metabolic liver damage

Obesity-related metabolic liver disease affects hundreds of millions of people worldwide, but only some fraction of those livers develop scarring, become inflamed, and eventually fail. University of Utah researchers have identified a protein, EFHD1, that appears to drive that transition by triggering an out-of-place antiviral immune response.

1 Sep 2026

Study identifies three distinct BMI trajectories among people with type 2 diabetes

A recent study by the University of Eastern Finland identified three distinct body mass index (BMI) trajectories among people with type 2 diabetes.

1 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

31 Aug 2026

CAC-based statin initiation shows no difference in major cardiovascular events

There was no difference in major cardiovascular events when statin initiation was based on coronary artery calcium compared with traditional risk factor assessment, according to results presented in a Hot Line session today at ESC Congress 2026.

31 Aug 2026

Routine referral of prostate cancer patients to a cardiovascular specialist fails to cut cardiac events

Men with prostate cancer have a high risk of heart disease, especially when treated with hormone therapy.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Starting statins early after diabetes diagnosis linked to lower dementia risk

Early initiation of statins after diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study presented today at ESC Congress 2026 and published in The Lancet Regional Health – Europe.

30 Aug 2026

Met-HeFT trial finds no cardiovascular benefit from metformin

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes.

30 Aug 2026